{
  "ticker": "DXB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972574",
  "id": "02972574",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250725",
  "time": "0835",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m436829nbkck.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Quarterly Report (Appendix 4C) Highlights:**  \n- **Licensing Deal (Amicus Therapeutics):**  \n  - Upfront payment of **US$30M (~AU$48M)** received.  \n  - Total potential milestone + royalties: **up to US$590M (~AU$940M)**.  \n- **Cumulative Licensing Deals:**  \n  - Total potential payments across all deals: **~AU$1.4B** (including AU$65M received to date).  \n- **Development Milestone (FUSO):**  \n  - Received **AU$4.2M** (pre-tax) for Japan trial activation.  \n- **Clinical Trial Progress (ACTION3 Phase 3):**  \n  - **219 patients** randomized/dosed.  \n  - FDA confirmed **proteinuria as acceptable primary endpoint** for US approval.  \n- **Financials:**  \n  - **Cash balance (30 June 2025): AU$68.3M** (up from AU$17.0M last quarter).  \n  - **Net operating cash inflow: AU$45.6M** (driven by licensing payments).  \n\n#### **Key Takeaways for Investors:**  \n1. **Significant liquidity boost** from licensing deals (~AU$65M cash in).  \n2. **Pipeline validation** via FDA endpoint alignment and global partnerships.  \n3. **Strong cash runway** to fund ongoing Phase 3 trial.  \n\n*No material capital-raising or trading halt details identified.*",
  "usage": {
    "prompt_tokens": 6310,
    "completion_tokens": 322,
    "total_tokens": 6632,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T22:50:41.274664"
}